AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Sylvie M. Guichard(Massachusetts Medical Society), Sabina Cosulich(Alzheimer’s Research UK)

Molecular Cancer Therapeutics

September 11, 2015

10.1158/1535-7163.mct-15-0365

Cited by 125

Related Papers

FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer

|Targeted Oncology|2023|30